These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22558238)

  • 21. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
    Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
    Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
    Calabrese M; Rinaldi F; Grossi P; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
    Mult Scler; 2010 Oct; 16(10):1220-8. PubMed ID: 20670981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.
    Portaccio E; Goretti B; Zipoli V; Nacmias B; Stromillo ML; Bartolozzi ML; Siracusa G; Guidi L; Federico A; Sorbi S; De Stefano N; Amato MP
    Mult Scler; 2009 Dec; 15(12):1489-94. PubMed ID: 19965518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
    Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
    JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.
    Sangalli F; Moiola L; Bucello S; Annovazzi P; Rizzo A; Radaelli M; Vitello G; Grimaldi LM; Ghezzi A; Martinelli V; Comi G
    Neurol Sci; 2011 Jan; 31 Suppl 3():299-302. PubMed ID: 20544247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.
    Calabrese M; Rinaldi F; Mattisi I; Grossi P; Favaretto A; Atzori M; Bernardi V; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P
    Neurology; 2010 Jan; 74(4):321-8. PubMed ID: 20101038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to detect cognitive dysfunction at early stages of multiple sclerosis?
    Deloire MS; Bonnet MC; Salort E; Arimone Y; Boudineau M; Petry KG; Brochet B
    Mult Scler; 2006 Aug; 12(4):445-52. PubMed ID: 16900758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
    Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.
    Svenningsson A; Falk E; Celius EG; Fuchs S; Schreiber K; Berkö S; Sun J; Penner IK;
    PLoS One; 2013; 8(3):e58643. PubMed ID: 23555589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Hao Q; Kanda M; Tani Y
    BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.